We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Studies on the Treatment of Cancer Cachexia with Megestrol Acetate plus Thalidomide.
- Authors
Wen, Hong-Sheng; Li, Xu; Cao, Yu-Zhu; Zhang, Cui-Cui; Yang, Fang; Shi, Yu-Ming; Peng, Li-Ming
- Abstract
Background: The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice. To date, practice guidelines for the prevention and treatment of CACS are lacking. The authors conducted a randomized study to confirm the effectiveness and safety of treatment of CACS utilizing megestrol acetate (MA) plus thalidomide. Methods: One hundred and two candidates with CACS were randomly assigned to two treatment groups (trial group and control group): the trial group received MA (160 mg po, bid) plus thalidomide (50 mg po, bid), while the control group received MA (160 mg po, bid) alone. Treatment duration was 8 weeks. Results: Analysis of the trial group demonstrated a significant increase from baseline in body weight (<0.01), quality of life (p = 0.02), appetite (p = 0.01), and grip strength (p = 0.01), and a significant decrease in fatigue, Glasgow Prognostic Score (p = 0.05), Eastern Cooperative Oncology Group performance status (p = 0.03), IL-6 (p < 0.01), and tumor necrosis factor-α (p = 0.02). In contrast, in the control group, endpoints with a significant improvement from baseline included body weight (p < 0.02) and appetite (p = 0.02). The mean changes in the endpoints from baseline in the trial group were significantly greater compared with the control group: in the primary endpoints, body weight (p = 0.05), fatigue (p < 0.01) and quality of life (p = 0.01), and in the secondary endpoints, grip strength (p = 0.05), Glasgow Prognostic Score (p = 0.02), Eastern Cooperative Oncology Group performance status (p = 0.02), IL-6 (p < 0.01) and tumor necrosis factor-α (p = 0.01). Toxicity was found to be relatively negligible in both groups. Conclusion: A combination regimen of MA and thalidomide is more effective than MA alone in the treatment of CACS. Copyright © 2013 S. Karger AG, Basel
- Subjects
CACHEXIA treatment; STEROIDS; THALIDOMIDE; MEDICAL practice; CLINICAL trials; BODY weight; TUMOR necrosis factors
- Publication
Chemotherapy (0009-3157), 2013, Vol 58, Issue 6, p461
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000346446